Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 643

1.

Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management.

O'Brien J, Taylor JP, Ballard C, Barker RA, Bradley C, Burns A, Collerton D, Dave S, Dudley R, Francis P, Gibbons A, Harris K, Lawrence V, Leroi I, McKeith I, Michaelides M, Naik C, O'Callaghan C, Olsen K, Onofrj M, Pinto R, Russell G, Swann P, Thomas A, Urwyler P, Weil RS, Ffytche D.

J Neurol Neurosurg Psychiatry. 2020 Mar 25. pii: jnnp-2019-322702. doi: 10.1136/jnnp-2019-322702. [Epub ahead of print] Review.

2.

Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.

Yu IS, Pereira AAL, Lee M, Korphaisarn K, Marshall J, Segelov E, O'Callaghan C, Lim HJ, Kopetz S, Loree JM.

Oncologist. 2020 Mar;25(3):229-234. doi: 10.1634/theoncologist.2019-0553. Epub 2019 Oct 22.

3.

Clinical features and management of children with primary ciliary dyskinesia in England.

Rubbo B, Best S, Hirst RA, Shoemark A, Goggin P, Carr SB, Chetcuti P, Hogg C, Kenia P, Lucas JS, Moya E, Narayanan M, O'Callaghan C, Williamson M, Walker WT; English National Children’s PCD Management Service.

Arch Dis Child. 2020 Mar 10. pii: archdischild-2019-317687. doi: 10.1136/archdischild-2019-317687. [Epub ahead of print]

PMID:
32156696
4.

Mind-wandering in Parkinson's disease hallucinations reflects primary visual and default network coupling.

Walpola IC, Muller AJ, Hall JM, Andrews-Hanna JR, Irish M, Lewis SJG, Shine JM, O'Callaghan C.

Cortex. 2020 Apr;125:233-245. doi: 10.1016/j.cortex.2019.12.023. Epub 2020 Jan 22.

PMID:
32058090
5.

Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study.

Hirst JA, Hill N, O'Callaghan CA, Lasserson D, McManus RJ, Ogburn E, Mena JMO, Shine B, Taylor CJ, Vazquez-Montes MD, Yang Y, Hobbs FR.

Br J Gen Pract. 2020 Mar 26;70(693):e285-e293. doi: 10.3399/bjgp20X708245. Print 2020 Apr.

6.

Dopamine and Functional Connectivity in Patients With Parkinson's Disease and Visual Hallucinations.

Powell A, Muller AJ, O'Callaghan C, Sourty M, Shine JM, Lewis SJG.

Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27995. [Epub ahead of print] No abstract available.

PMID:
32034927
7.

Context-Dependent Roles for SIRT2 and SIRT3 in Tumor Development Upon Calorie Restriction or High Fat Diet.

Ahmed MA, O'Callaghan C, Chang ED, Jiang H, Vassilopoulos A.

Front Oncol. 2020 Jan 8;9:1462. doi: 10.3389/fonc.2019.01462. eCollection 2019.

8.

Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort.

Fassad MR, Patel MP, Shoemark A, Cullup T, Hayward J, Dixon M, Rogers AV, Ollosson S, Jackson C, Goggin P, Hirst RA, Rutman A, Thompson J, Jenkins L, Aurora P, Moya E, Chetcuti P, O'Callaghan C, Morris-Rosendahl DJ, Watson CM, Wilson R, Carr S, Walker W, Pitno A, Lopes S, Morsy H, Shoman W, Pereira L, Constant C, Loebinger MR, Chung EMK, Kenia P, Rumman N, Fasseeh N, Lucas JS, Hogg C, Mitchison HM.

J Med Genet. 2019 Dec 25. pii: jmedgenet-2019-106501. doi: 10.1136/jmedgenet-2019-106501. [Epub ahead of print]

PMID:
31879361
9.

The multifaceted nature of impulsivity in Parkinson's disease.

O'Callaghan C.

Brain. 2019 Dec 1;142(12):3666-3669. doi: 10.1093/brain/awz349. No abstract available.

PMID:
31789368
10.

Effect of Salt Supplementation on Sympathetic Activity and Endothelial Function in Salt-Sensitive Type 2 Diabetes.

Baqar S, Kong YW, Chen AX, O'Callaghan C, MacIsaac RJ, Bouterakos M, Lambert GW, Jerums G, Lambert EE, Ekinci EI.

J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: dgz219. doi: 10.1210/clinem/dgz219.

PMID:
31761946
11.

Ciliated Epithelial Cell Differentiation at Air-Liquid Interface Using Commercially Available Culture Media.

Lee DDH, Petris A, Hynds RE, O'Callaghan C.

Methods Mol Biol. 2020;2109:275-291. doi: 10.1007/7651_2019_269.

PMID:
31707647
12.

Response.

Lucas JS, Rubbo B, Jackson CL, Hirst RA, Hogg C, O'Callaghan C, Reading I, Shoemark A.

Chest. 2019 Nov;156(5):1033-1034. doi: 10.1016/j.chest.2019.07.001. No abstract available.

PMID:
31699225
13.

Pathway Commons 2019 Update: integration, analysis and exploration of pathway data.

Rodchenkov I, Babur O, Luna A, Aksoy BA, Wong JV, Fong D, Franz M, Siper MC, Cheung M, Wrana M, Mistry H, Mosier L, Dlin J, Wen Q, O'Callaghan C, Li W, Elder G, Smith PT, Dallago C, Cerami E, Gross B, Dogrusoz U, Demir E, Bader GD, Sander C.

Nucleic Acids Res. 2020 Jan 8;48(D1):D489-D497. doi: 10.1093/nar/gkz946.

PMID:
31647099
14.

Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.

Yu IS, Pereira AAL, Lee M, Korphaisarn K, Marshall J, Segelov E, O'Callaghan C, Lim HJ, Kopetz S, Loree JM.

Oncologist. 2019 Oct 22. pii: theoncologist.2019-0553. doi: 10.1634/theoncologist.2019-0553. [Epub ahead of print]

15.

Palliative Caregivers' Spirituality, Views About Spiritual Care, and Associations With Spiritual Well-Being: A Mixed Methods Study.

O'Callaghan C, Seah D, Clayton JM, Welz M, Kissane D, Georgousopoulou EN, Michael N.

Am J Hosp Palliat Care. 2020 Apr;37(4):305-313. doi: 10.1177/1049909119877351. Epub 2019 Sep 24.

PMID:
31550902
16.

Disinhibition in Frontotemporal Dementia and Alzheimer's Disease: A Neuropsychological and Behavioural Investigation.

Mariano LI, O'Callaghan C, Guimarães HC, Gambogi LB, da Silva TBL, Yassuda MS, Amaral JS, Caramelli P, Hornberger M, Teixeira AL, de Souza LC.

J Int Neuropsychol Soc. 2020 Feb;26(2):163-171. doi: 10.1017/S1355617719000973. Epub 2019 Sep 23.

PMID:
31543087
17.

Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis.

Taylor KS, Mclellan J, Verbakel JY, Aronson JK, Lasserson DS, Pidduck N, Roberts N, Fleming S, O'Callaghan CA, Bankhead CR, Banerjee A, Hobbs FR, Perera R.

BMJ Open. 2019 Sep 20;9(9):e030596. doi: 10.1136/bmjopen-2019-030596.

18.

Reduced kidney function at presentation in unselected acute emergency medical admissions: incidence, outcome and associated factors.

Yang E, Chalisey A, Reschen ME, Shine B, Lasserson DS, O'Callaghan CA.

Acute Med. 2019;18(3):158-164.

PMID:
31536053
19.

Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes.

Chen AX, Moran JL, Libianto R, Baqar S, O'Callaghan C, MacIsaac RJ, Jerums G, Ekinci EI.

J Hum Hypertens. 2020 Feb;34(2):143-150. doi: 10.1038/s41371-019-0238-3. Epub 2019 Sep 9.

PMID:
31501493
20.

Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group - Is trial design a barrier?

Hernandez-Torres C, Cheung WY, Kong S, O'Callaghan CJ, Hsu T.

J Geriatr Oncol. 2020 Apr;11(3):455-462. doi: 10.1016/j.jgo.2019.08.004. Epub 2019 Aug 28.

PMID:
31473189
21.

A Touchscreen Motivation Assessment Evaluated in Huntington's Disease Patients and R6/1 Model Mice.

Heath CJ, O'Callaghan C, Mason SL, Phillips BU, Saksida LM, Robbins TW, Barker RA, Bussey TJ, Sahakian BJ.

Front Neurol. 2019 Aug 9;10:858. doi: 10.3389/fneur.2019.00858. eCollection 2019.

22.

Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression.

McCarthy MT, Lin D, Soga T, Adam J, O'Callaghan CA.

Eur J Immunol. 2020 Jan;50(1):130-137. doi: 10.1002/eji.201847948. Epub 2019 Sep 12.

23.

Characteristics of patients with cancer who die by suicide: Coronial case series in an Australian state.

Dwyer J, Dwyer J, Hiscock R, O'Callaghan C, Taylor K, Ross M, Bugeja L, Philip J.

Psychooncology. 2019 Nov;28(11):2195-2200. doi: 10.1002/pon.5207. Epub 2019 Aug 30.

PMID:
31418507
24.

Patients' and Caregivers' Contested Perspectives on Spiritual Care for Those Affected by Advanced Illnesses: A Qualitative Descriptive Study.

O'Callaghan C, Brooker J, de Silva W, Glenister D, Melia Cert A 4th, Symons X, Kissane D, Michael N.

J Pain Symptom Manage. 2019 Dec;58(6):977-988. doi: 10.1016/j.jpainsymman.2019.08.004. Epub 2019 Aug 9.

PMID:
31404641
25.

Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?

Hanna TP, Nguyen P, Pater J, O'Callaghan CJ, Mittmann N, Earle CC, Tu D, Jonker D, Hay AE.

J Oncol Pract. 2019 Sep;15(9):e807-e824. doi: 10.1200/JOP.18.00691. Epub 2019 Jul 15.

PMID:
31306036
26.

A genetics-led approach defines the drug target landscape of 30 immune-related traits.

Fang H; ULTRA-DD Consortium, De Wolf H, Knezevic B, Burnham KL, Osgood J, Sanniti A, Lledó Lara A, Kasela S, De Cesco S, Wegner JK, Handunnetthi L, McCann FE, Chen L, Sekine T, Brennan PE, Marsden BD, Damerell D, O'Callaghan CA, Bountra C, Bowness P, Sundström Y, Milani L, Berg L, Göhlmann HW, Peeters PJ, Fairfax BP, Sundström M, Knight JC.

Nat Genet. 2019 Jul;51(7):1082-1091. doi: 10.1038/s41588-019-0456-1. Epub 2019 Jun 28.

PMID:
31253980
27.

Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD.

Feakins B, Oke J, McFadden E, Aronson J, Lasserson D, O'Callaghan C, Taylor C, Hill N, Stevens R, Perera R.

BMJ Open. 2019 Jun 12;9(6):e028062. doi: 10.1136/bmjopen-2018-028062. Erratum in: BMJ Open. 2019 Jul 1;9(7):e028062corr1.

28.

Meta-analytic Evidence for the Plurality of Mechanisms in Transdiagnostic Structural MRI Studies of Hallucination Status.

Rollins CPE, Garrison JR, Simons JS, Rowe JB, O'Callaghan C, Murray GK, Suckling J.

EClinicalMedicine. 2019 Feb 21;8:57-71. doi: 10.1016/j.eclinm.2019.01.012. eCollection 2019 Feb.

29.

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial.

Hoch JS, Hay A, Isaranuwatchai W, Thavorn K, Leighl NB, Tu D, Trenaman L, Dewa CS, O'Callaghan C, Pater J, Jonker D, Chen BE, Mittmann N.

BMC Cancer. 2019 Jun 7;19(1):552. doi: 10.1186/s12885-019-5779-x.

30.

Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance.

Kulkoyluoglu-Cotul E, Smith BP, Wrobel K, Zhao YC, Chen KLA, Hieronymi K, Imir OB, Duong K, O'Callaghan C, Mehta A, Sahoo S, Haley B, Chang H, Landesman Y, Madak-Erdogan Z.

Cancers (Basel). 2019 Apr 4;11(4). pii: E479. doi: 10.3390/cancers11040479.

31.

Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson's disease.

Hall JM, O'Callaghan C, Muller AJ, Ehgoetz Martens KA, Phillips JR, Moustafa AA, Lewis SJG, Shine JM.

Netw Neurosci. 2019 Mar 1;3(2):521-538. doi: 10.1162/netn_a_00078. eCollection 2019.

32.

A retrospective analysis of outcomes in low- and intermediate-high-risk pulmonary embolism patients managed on an ambulatory medical unit in the UK.

Reschen ME, Raby J, Bowen J, Singh S, Lasserson D, O'Callaghan CA.

ERJ Open Res. 2019 Apr 8;5(2). pii: 00184-2018. doi: 10.1183/23120541.00184-2018. eCollection 2019 Apr.

33.

Dopamine depletion alters macroscopic network dynamics in Parkinson's disease.

Shine JM, Bell PT, Matar E, Poldrack RA, Lewis SJG, Halliday GM, O'Callaghan C.

Brain. 2019 Apr 1;142(4):1024-1034. doi: 10.1093/brain/awz034.

PMID:
30887035
34.

Accuracy of High-Speed Video Analysis to Diagnose Primary Ciliary Dyskinesia.

Rubbo B, Shoemark A, Jackson CL, Hirst R, Thompson J, Hayes J, Frost E, Copeland F, Hogg C, O'Callaghan C, Reading I, Lucas JS; National PCD Service, UK.

Chest. 2019 May;155(5):1008-1017. doi: 10.1016/j.chest.2019.01.036. Epub 2019 Feb 28.

35.

Hippocampal atrophy and intrinsic brain network dysfunction relate to alterations in mind wandering in neurodegeneration.

O'Callaghan C, Shine JM, Hodges JR, Andrews-Hanna JR, Irish M.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3316-3321. doi: 10.1073/pnas.1818523116. Epub 2019 Feb 4.

36.

Timing of palliative care referral and aggressive cancer care toward the end-of-life in pancreatic cancer: a retrospective, single-center observational study.

Michael N, Beale G, O'Callaghan C, Melia A, DeSilva W, Costa D, Kissane D, Shapiro J, Hiscock R.

BMC Palliat Care. 2019 Jan 28;18(1):13. doi: 10.1186/s12904-019-0399-4.

37.

Informant- and Self-Appraisals on the Psychosis and Hallucinations Questionnaire (PsycH-Q) Enhances Detection of Visual Hallucinations in Parkinson's Disease.

Muller AJ, Mills JMZ, O'Callaghan C, Naismith SL, Clouston PD, Lewis SJG, Shine JM.

Mov Disord Clin Pract. 2018 Nov 8;5(6):607-613. doi: 10.1002/mdc3.12683. eCollection 2018 Nov-Dec.

38.

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R.

Curr Oncol. 2018 Dec;25(6):e516-e526. doi: 10.3747/co.25.4069. Epub 2018 Dec 1.

39.

Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.

Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ.

Clin Colorectal Cancer. 2019 Mar;18(1):e140-e149. doi: 10.1016/j.clcc.2018.11.006. Epub 2018 Nov 28.

PMID:
30595557
40.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.

PMID:
30575490
41.

Mutations in Outer Dynein Arm Heavy Chain DNAH9 Cause Motile Cilia Defects and Situs Inversus.

Fassad MR, Shoemark A, Legendre M, Hirst RA, Koll F, le Borgne P, Louis B, Daudvohra F, Patel MP, Thomas L, Dixon M, Burgoyne T, Hayes J, Nicholson AG, Cullup T, Jenkins L, Carr SB, Aurora P, Lemullois M, Aubusson-Fleury A, Papon JF, O'Callaghan C, Amselem S, Hogg C, Escudier E, Tassin AM, Mitchison HM.

Am J Hum Genet. 2018 Dec 6;103(6):984-994. doi: 10.1016/j.ajhg.2018.10.016. Epub 2018 Nov 21.

42.

Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes.

Hay AE, Pater JL, Corn E, Han L, Camacho X, O'Callaghan C, Chong N, Bell EN, Tu D, Earle CC.

Clin Trials. 2019 Feb;16(1):14-17. doi: 10.1177/1740774518815653. Epub 2018 Nov 22.

PMID:
30466310
43.

Author Correction: Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.

Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, Walter TS, O'Callaghan CA, Borrow P, Toebes M, Hansen SG, Sacha JB, Abdulhaqq S, Greene JM, Früh K, Marshall E, Picker LJ, Jones EY, McMichael AJ, Gillespie GM.

Nat Commun. 2018 Nov 13;9(1):4833. doi: 10.1038/s41467-018-07304-9.

44.

[Spanish adaptation of the free OxMaR software for minimization and randomization of clinical studies].

Guillaumes S, O'Callaghan CA.

Gac Sanit. 2019 Jul - Aug;33(4):395-397. doi: 10.1016/j.gaceta.2018.07.013. Epub 2018 Nov 1. Spanish.

45.

Biallelic Mutations in LRRC56, Encoding a Protein Associated with Intraflagellar Transport, Cause Mucociliary Clearance and Laterality Defects.

Bonnefoy S, Watson CM, Kernohan KD, Lemos M, Hutchinson S, Poulter JA, Crinnion LA, Berry I, Simmonds J, Vasudevan P, O'Callaghan C, Hirst RA, Rutman A, Huang L, Hartley T, Grynspan D, Moya E, Li C, Carr IM, Bonthron DT, Leroux M; Care4Rare Canada Consortium, Boycott KM, Bastin P, Sheridan EG.

Am J Hum Genet. 2018 Nov 1;103(5):727-739. doi: 10.1016/j.ajhg.2018.10.003.

46.

Novel Smartphone Interventions Improve Cognitive Flexibility and Obsessive-Compulsive Disorder Symptoms in Individuals with Contamination Fears.

Jalal B, Brühl A, O'Callaghan C, Piercy T, Cardinal RN, Ramachandran VS, Sahakian BJ.

Sci Rep. 2018 Oct 23;8(1):14923. doi: 10.1038/s41598-018-33142-2.

47.

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14.

48.

Age-related changes in the temporal focus and self-referential content of spontaneous cognition during periods of low cognitive demand.

Irish M, Goldberg ZL, Alaeddin S, O'Callaghan C, Andrews-Hanna JR.

Psychol Res. 2019 Jun;83(4):747-760. doi: 10.1007/s00426-018-1102-8. Epub 2018 Oct 6.

PMID:
30291418
49.

The Future Is Now-Prospective Study of Radiosurgery for More Than 4 Brain Metastases to Start in 2018!

Roberge D, Brown PD, Whitton A, O'Callaghan C, Leis A, Greenspoon J, Smith GL, Hu JJ, Nichol A, Winch C, Chan MD.

Front Oncol. 2018 Sep 13;8:380. doi: 10.3389/fonc.2018.00380. eCollection 2018.

50.

Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesia.

Best S, Shoemark A, Rubbo B, Patel MP, Fassad MR, Dixon M, Rogers AV, Hirst RA, Rutman A, Ollosson S, Jackson CL, Goggin P, Thomas S, Pengelly R, Cullup T, Pissaridou E, Hayward J, Onoufriadis A, O'Callaghan C, Loebinger MR, Wilson R, Chung EM, Kenia P, Doughty VL, Carvalho JS, Lucas JS, Mitchison HM, Hogg C.

Thorax. 2019 Feb;74(2):203-205. doi: 10.1136/thoraxjnl-2018-212104. Epub 2018 Aug 30.

PMID:
30166424

Supplemental Content

Loading ...
Support Center